Evidence map›Paper›PMID 40406736›Full record

ArticleJAC-antimicrobial resistance2025

High-dose isoniazid for TB with low-to-moderate isoniazid resistance after 1 week of treatment.

U D Ranganathan, S E Smith-Jeffcoat, S Balaji, K Devika, D Nair, B Devaleenal Daniel, R Srinivasan, M Baskaran, D RaviKumar, D Sangamithirai and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

U D RanganathanDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
S E Smith-JeffcoatDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
S BalajiDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
K DevikaDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
D NairDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
B Devaleenal DanielDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
R SrinivasanDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
M BaskaranDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
D RaviKumarDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
D SangamithiraiDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
G RadhikaDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
G MangalambalDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
J LavanyaState Tuberculosis Cell, Greater Chennai Corporation, Chennai, Tamil Nadu, India.
K MaheswaranGovernment Hospital for Thoracic Medicine, Tambaram, Tamil Nadu, India.
S KumarGovernment Hospital for Thoracic Medicine, Tambaram, Tamil Nadu, India.
R SridharGovernment Hospital for Thoracic Medicine, Tambaram, Tamil Nadu, India.
S TripathyDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
S SwaminathanDepartments of Microbiology, Immunology and Clinical Research, Indian Council for Medical Research-National Institute of Research for Tuberculosis, Chennai, India.
K D EisenachTB or Not TB Consulting, LLC, Little Rock, AR, USA.
J P CegielskiDivision of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the effect of high-dose isoniazid in patients with isoniazid-resistant TB by its bactericidal activity after 1 or more weeks of treatment. Subjects and methods: Using the rapid direct method of phenotypic drug susceptibility testing, we screened persons with positive sputum microscopy results and genotypic drug resistance for isoniazid resistance. Those with no growth at a critical concentration of 2.0 mg/L were invited to participate in a trial of high-dose isoniazid monotherapy lasting 6 days. After 3 days of no treatment, patients received isoniazid 15 mg/kg and were followed with serial quantitative sputum cultures from Days 0 to 6. Results: We enrolled 15 patients after a median of 2 weeks standard first-line treatment. Their median bacillary count on Day 0 was 4.9 log Conclusions: The utility of high-dose isoniazid against low-level isoniazid resistance beyond the first 2 weeks of chemotherapy should be reconsidered.

Identifiers

PMID40406736
PMCPMC12096161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.